Pacific Biosciences of California (NASDAQ:PACB) Insider Oene Mark Van Sells 55,107 Shares

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Oene Mark Van sold 55,107 shares of Pacific Biosciences of California stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.63, for a total value of $89,824.41. Following the transaction, the insider owned 1,742,638 shares of the company’s stock, valued at $2,840,499.94. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Oene Mark Van also recently made the following trade(s):

• On Tuesday, February 17th, Oene Mark Van sold 129,790 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.58, for a total value of $205,068.20.

Pacific Biosciences of California Price Performance

Pacific Biosciences of California stock traded up $0.05 during mid-day trading on Thursday, hitting $1.68. 4,308,048 shares of the company were exchanged, compared to its average volume of 7,583,859. Pacific Biosciences of California, Inc. has a 12-month low of $0.85 and a 12-month high of $2.73. The company has a market capitalization of $507.21 million, a P/E ratio of -0.91 and a beta of 2.27. The business’s 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.77. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40.

Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%.The business had revenue of $44.65 million for the quarter, compared to analyst estimates of $44.60 million. Analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year.

Key Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Management will participate in a TD Cowen health-care conference fireside chat on March 2, providing a near-term investor event where the company may update guidance, commercialization progress, or product cadence — a potential catalyst if management delivers constructive news. Read More.
• Neutral Sentiment: Despite the sales, insiders retain large holdings after the transactions (final reported post-sale holdings: Michele Farmer ~219k shares; Christian O. Henry ~2.67M shares; Oene Mark Van ~1.74M shares), which may signal liquidity-taking rather than full exits. (See SEC filings below for details.)
• Negative Sentiment: Heavy insider selling reported Feb. 17–18: combined sales by multiple executives totaled roughly 707,731 shares for about $1.13M. Notable filings: Christian O. Henry sold ~472,667 shares across two trades, Michele Farmer sold ~50,167 shares, and Oene Mark Van sold ~184,897 shares — each reducing their stakes by mid-single to low-double-digit percentages. Large, clustered insider sales can raise investor concern about near-term outlook or signal personal diversification, and may pressure sentiment until management commentary clarifies reasons. SEC filings: Christian O. Henry Read More.; Michele Farmer Read More.; Oene Mark Van Read More..

Institutional Investors Weigh In On Pacific Biosciences of California

Institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC boosted its position in Pacific Biosciences of California by 20.5% during the 4th quarter. ARK Investment Management LLC now owns 37,264,228 shares of the biotechnology company’s stock worth $69,684,000 after purchasing an additional 6,340,125 shares during the period. Vanguard Group Inc. raised its position in Pacific Biosciences of California by 2.3% in the third quarter. Vanguard Group Inc. now owns 16,379,972 shares of the biotechnology company’s stock valued at $20,966,000 after purchasing an additional 362,797 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pacific Biosciences of California by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 7,078,744 shares of the biotechnology company’s stock worth $13,241,000 after purchasing an additional 172,089 shares in the last quarter. Millennium Management LLC boosted its position in shares of Pacific Biosciences of California by 500.9% in the third quarter. Millennium Management LLC now owns 4,916,795 shares of the biotechnology company’s stock worth $6,293,000 after buying an additional 4,098,555 shares during the period. Finally, Casdin Capital LLC boosted its position in shares of Pacific Biosciences of California by 483.6% in the fourth quarter. Casdin Capital LLC now owns 4,223,767 shares of the biotechnology company’s stock worth $7,898,000 after buying an additional 3,500,000 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PACB. Weiss Ratings reissued a “sell (e+)” rating on shares of Pacific Biosciences of California in a research note on Thursday, January 22nd. Barclays boosted their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Piper Sandler increased their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Finally, Stephens raised their price objective on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2.20.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.